Friday, September 29, 2023 7:47:37 PM
Here was the news:
Why Is Obesity Focused Structure Therapeutics Stock Trading Higher Today?
BENZINGA 8:55 AM ET Sep-29-2023
Structure Therapeutics Inc (NASDAQ:GPCR) released results from the Phase 1b multiple ascending dose (MAD) study of GSBR-1290 in healthy, overweight, or obese individuals.
GSBR-1290 is an oral GLP-1 receptor agonist, similar to Novo Nordisk A/S's (NYSE:NVO) popular drug, Wegovy (semaglutide).
In the 28-day study, GSBR-1290 demonstrated significant weight loss supporting once-daily (QD) dosing.
GSBR-1290 demonstrated reductions in mean body weight ranging up to 4.9 kg compared to baseline and up to 4.9% placebo-adjusted.
The company is expected to report topline data from the type 2 diabetes cohort of the Phase 2a study in the latter half of Q4 of 2023.
Structure continues to plan to initiate two Phase 2b studies of GSBR-1290 in 2024. The type 2 diabetes study is expected to include approximately 500 individuals.
The company is also planning a separate formulation bridging PK study to support the planned transition from capsules to tablets, which is expected to be initiated in Q4 of 2023 and completed in Q2 of 2024. Pending supportive data from this bridging study, the tablet formulation would be used in future GSBR-1290 studies starting with the planned Phase 2b studies.
Concurrently, Structure Therapeutics announced a private placement of 21.6 million shares and 2.4 million newly designated non-voting shares at $12.49 per share, with gross proceeds of $300 million.
Net proceeds, along with existing cash, cash equivalents, and short-term investments, are expected to extend the cash runway through the end of 2026.
Price Action: GPCR shares are 68.1% at $62.98 during the premarket session on the last check Friday.
Recent GPCR News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:56:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:10:36 PM
- Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights • GlobeNewswire Inc. • 05/09/2024 08:05:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/08/2024 09:19:19 PM
- Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference • GlobeNewswire Inc. • 03/08/2024 09:05:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/08/2024 02:19:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 01:43:20 PM
- Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights • GlobeNewswire Inc. • 03/08/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 01:28:47 PM
- Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study • GlobeNewswire Inc. • 12/18/2023 12:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/30/2023 05:15:14 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 11/17/2023 10:25:30 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/17/2023 09:55:37 PM
- Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend] • Edgar (US Regulatory) • 11/17/2023 09:51:18 PM
- Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend] • Edgar (US Regulatory) • 11/16/2023 10:13:32 PM
- Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights • GlobeNewswire Inc. • 11/14/2023 09:10:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/29/2023 11:50:20 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/29/2023 11:38:34 AM
- Structure Therapeutics Announces $300 Million Private Placement Equity Financing • GlobeNewswire Inc. • 09/29/2023 11:32:00 AM
- Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update • GlobeNewswire Inc. • 09/29/2023 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 08:41:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 08:19:34 PM
- Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights • GlobeNewswire Inc. • 08/10/2023 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/04/2023 08:30:21 PM
- Structure Therapeutics Appoints Ted W. Love, M.D., to Board of Directors • GlobeNewswire Inc. • 08/03/2023 09:32:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM